Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 16/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.79 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.71 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.71 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241634 | 0.88 | RAF1 (0.79) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10220054 | 0.88 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3213560 | 0.84 | MAPK14 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3245607 | 0.83 | MAPK14 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10220677 | 0.83 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3244244 | 0.81 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3225122 | 0.79 | RAF1 (0.67) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3246160 | 0.77 | MAPK14 (0.73) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3220107 | 0.77 | MAPK14 (1.00) | RAF1MAPK14KDM4EMEN1MAPT | |
| SCHEMBL3244311 | 0.76 | MAPK14 (0.74) | RAF1MAPK14MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | LY96, HSPA2, BRAF | RAF1 77/4885MAPK14 1605/4885MAPK13 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.